Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 13, 2009 - Issue 8
Submit an article Journal homepage
279
Views
53
CrossRef citations to date
0
Altmetric
Reviews

Virus maturation as a new HIV-1 therapeutic target

Catherine S Adamson Virus–Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Building 535/Room 108, 1050 Boyles Street, Frederick, MD 21702 – 1201, USA +1 301 846 6223; +1 301 846 6777; [email protected]
,
Karl Salzwedel Panacos Pharmaceuticals, 209 Perry Parkway, Gaithersburg, MD 20877, USA; (Current address) Division of AIDS, NIAID/NIH, 6700-B Rockledge Dr., Rm. 4149, Bethesda, MD 20892, USA
&
Eric O Freed Virus–Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute at Frederick, Building 535/Room 108, 1050 Boyles Street, Frederick, MD 21702 – 1201, USA +1 301 846 6223; +1 301 846 6777; [email protected]
, PhD
Pages 895-908 | Published online: 17 Jun 2009

Bibliography

  • UNAIDS. Report on the global AIDS epidemic. UNAIDS, 2008
  • Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006;368:489-504
  • Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust 2007;186:146-51
  • Thomson MM, Perez-Alvarez L, Najera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2002;2:461-71
  • Svarovskaia ES, Cheslock SR, Zhang WH, et al. Retroviral mutation rates and reverse transcriptase fidelity. Front Biosci 2003;8:d117-34
  • Rambaut A, Posada D, Crandall KA, Holmes EC. The causes and consequences of HIV evolution. Nat Rev Genet 2004;5:52-61
  • Najera R, Delgado E, Perez-Alvarez L, Thomson MM. Genetic recombination and its role in the development of the HIV-1 pandemic. AIDS 2002;16(Suppl 4):S3-16
  • Hu WS, Rhodes T, Dang Q, Pathak V. Retroviral recombination: review of genetic analyses. Front Biosci 2003;8:d143-55
  • Emini EA, Fan HY. Immunological and pharmacological approaches to the control of retroviral infections. In: Coffin JM, Hughes SH, Varmus HE, editors, Retroviruses. Cold Spring Harbor Laboratory Press, 1997;637-706
  • Temesgen Z, Cainelli F, Poeschla EM, et al. Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. Lancet Infect Dis 2006;6:496-507
  • Perno CF, Moyle G, Tsoukas C, et al. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J Med Virol 2008;80:565-76
  • Nunez M, Soriano V. Salvage therapy for HIV infection: when and how. AIDS Patient Care STDS 2000;14:465-76
  • Richman DD. HIV chemotherapy. Nature 2001;410:995-1001
  • Hughes A, Barber T, Nelson M. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J Infect 2008;57:1--10
  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. Available from: http://aidsinfo.nih.gov/ [Accessed 3 November 2008]
  • Este JA, Telenti A. HIV entry inhibitors. Lancet 2007;370:81-8
  • Nair V, Chi G. HIV integrase inhibitors as therapeutic agents in AIDS. Rev Med Virol 2007;17:277-95
  • Adamson CS, Freed EO. Recent progress in antiretrovirals–lessons from resistance. Drug Discov Today 2008;13:424-32
  • Evering TH, Markowitz M. Raltegravir: an integrase inhibitor for HIV-1. Expert Opin Investig Drugs 2008;17:413-22
  • Soriano V, Geretti AM, Perno CF, et al. Optimal use of maraviroc in clinical practice. AIDS 2008;22:2231-40
  • Daar ES. Emerging resistance profiles of newly approved antiretroviral drugs. Top HIV Med 2008;16:110-6
  • Vogt VM. Proteolytic processing and particle maturation. Curr Top Microbiol Immunol 1996;214:95-131
  • Freed EO. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998;251:1-5
  • Gottlinger HG. The HIV-1 assembly machine. AIDS 2001;15(Suppl 5):13-20
  • Demirov DG, Freed EO. Retrovirus budding. Virus Res 2004;106:87-102
  • Morita E, Sundquist WI. Retrovirus budding. Annu Rev Cell Dev Biol 2004;20:395-425
  • Adamson CS, Freed EO. HIV-1 assembly, release and maturation. In: Jeang K-T, editor. Advances in Pharmacolgy, HIV-1: Molecular Biology and Pathogenesis: Viral Mechansims. Elsevier, 2007;347-87
  • Ganser-Pornillos BK, Yeager M, Sundquist WI. The structural biology of HIV assembly. Curr Opin Struct Biol 2008;18:203-17
  • Krausslich HG, Schneider H, Zybarth G, et al. Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli. J Virol 1988;62:4393-7
  • Mervis RJ, Ahmad N, Lillehoj EP, et al. The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors. J Virol 1988;62:3993-4002
  • Erickson-Viitanen S, Manfredi J, Viitanen P, et al. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res Hum Retroviruses 1989;5:577-91
  • Tritch RJ, Cheng YE, Yin FH, Erickson-viitanen S. Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein. J Virol 1991;65:922-30
  • Pettit SC, Moody MD, Wehbie RS, et al. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol 1994;68:8017-27
  • Wiegers K, Rutter G, Kottler H, et al. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol 1998;72:2846-54
  • Kaplan AH, Zack JA, Knigge M, et al. Partial inhibition of the Human Immunodeficiency Virus Type 1 protease results in abbreant virus assembly and the formation of non-infectious particles. J Virol 1993;67:4050-5
  • Krausslich HG, Facke M, Heuser AM, et al. The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity. J Virol 1995;69:3407-19
  • Accola MA, Hoglund S, Gottlinger HG. A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly. J Virol 1998;72:2072-8
  • Pettit SC, Henderson GJ, Schiffer CA, Swanstrom R. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J Virol 2002;76:10226-33
  • Li F, Goila-Gaur R, Salzwedel K, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA 2003;100:13555-60
  • Zhou J, Yuan X, Dismuke D, et al. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol 2004;78:922-9
  • Wlodawer A, Erickson JW. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem 1993;62:543-85
  • Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 1998;27:249-84
  • Temesgen Z, Warnke D, Kasten MJ. Current status of antiretroviral therapy. Expert Opin Pharmacother 2006;7:1541-54
  • Mitsuya H, Maeda K, Das D, Ghosh AK. Development of protease inhibitors and the fight with drug-resistant HIV-1 variants. Adv Pharmacol 2008;56:169-97
  • Aiken C, Chen CH. Betulinic acid derivatives as HIV-1 antivirals. Trends Mol Med 2005;11:31-6
  • Salzwedel K, Martin DE, Sakalian M. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev 2007;9:162-72
  • Fujioka T, Kashiwada Y, Kilkuskie RE, et al. Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod 1994;57:243-7
  • Adamson CS, Waki K, Ablan SD, et al. Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J Virol 2009;83:4884-94
  • Dafonseca S, Blommaert A, Coric P, et al. The 3-O-(3',3'-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells. Antivir Ther 2007;12:1185-203
  • Adamson CS, Ablan SD, Boeras I, et al. In vitro resistance to the Human Immunodeficiency Virus Type 1 maturation inhibitor Pa-457 (Bevirimat). J Virol 2006;80:10957-71
  • Li F, Zoumplis D, Matallana C, et al. Determinants of activity of the HIV-1 maturation inhibitor PA-457. Virology 2006;356:217-24
  • Zhou J, Chen CH, Aiken C. Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag. J Virol 2006;80:12095-101
  • Zhou J, Chen CH, Aiken C. The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid. Retrovirology 2004;1:15
  • Zhou J, Huang L, Hachey DL, et al. Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles. J Biol Chem 2005;280:42149-55
  • Sakalian M, Mcmurtrey CP, Deeg FJ, et al. 3-o-(3',3'-dimethysuccinyl) betulinic Acid inhibits maturation of the human immunodeficiency virus type 1 gag precursor assembled in vitro. J Virol 2006;80:5716-22
  • Gamble TR, Yoo S, Vajdos FF, et al. Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science 1997;278:849-53
  • Worthylake DK, Wang H, Yoo S, et al. Structures of the HIV-1 capsid protein dimerization domain at 2.6 A resolution. Acta Crystallogr D Biol Crystallogr 1999;55:85-92
  • Newman JL, Butcher EW, Patel DT, et al. Flexibility in the P2 domain of the HIV-1 Gag polyprotein. Protein Sci 2004;13:2101-7
  • Morellet N, Druillennec S, Lenoir C, et al. Helical structure determined by NMR of the HIV-1 (345-392)Gag sequence, surrounding p2: implications for particle assembly and RNA packaging. Protein Sci 2005;14:375-86
  • Wright ER, Schooler JB, Ding HJ, et al. Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells. Embo J 2007;26:2218-26
  • Stoddart CA, Joshi P, Sloan B, et al. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS ONE 2007;2:e1251
  • Wen Z, Stern ST, Martin DE, et al. Structural characterization of anti-HIV drug candidate PA-457 [3-O-(3',3'-dimethylsuccinyl)-betulinic acid] and its acyl glucuronides in rat bile and evaluation of in vitro stability in human and animal liver microsomes and plasma. Drug Metab Dispos 2006;34:1436-42
  • Martin DE, Blum R, Doto J, et al. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. Clin Pharmacokinet 2007;46:589-98
  • Martin DE, Blum R, Wilton J, et al. Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob Agents Chemother 2007;51:3063-6
  • Smith PF, Ogundele A, Forrest A, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 2007;51:3574-81
  • Wen Z, Martin DE, Bullock P, et al. Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP-glucuronosyltransferases and species differences. Drug Metab Dispos 2007;35:440-8
  • Bullock P, Larsen D, Press R, et al. The absorption, distribution, metabolism and elimination of bevirimat in rats. Biopharm Drug Dispos 2008;29:396-405
  • Mccallister S, Lalezari J, Richmond G, et al. HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457). Presented at the XVII International HIV Drug Resistance Workshop. Sitges, Spain; 10 – 14 June 2008
  • Salzwedel K, Reddick M, Matallana C, et al. Role of Gag polymorphisms in HIV-1 sensitivity to the maturation inhibitor bevirimat. Presented at the XVII International HIV Drug Resistance Workshop. Sitges, Spain; 10 – 14 June 2008
  • Margot NA, Gibbs CS, Miller MD. Phenotyphic susceptibility to bevirimat among HIV-Infected patient isolates without prior exposure to bevirimat. Presented at the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; 8 - 11 February 2009
  • Salzwedel K, Hamy F, Louvel S, et al. Suceptibility of diverse HIV-1 patient isolates to the maturation inhibitor bevirimat (MPC-4326) is determined by clade-specific polymorphisms in Gag CA-SP1. Presented at the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; 8 - 11 February 2009;52:2185-88
  • Van Baelen K, Salzwedel K, Rondelez E, et al. HIV-1 Susceptibility to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag SP1. Antimicrob Agents Chemother 2009
  • Yebra G, Holgun A. The maturation inhibitor bevirimat (PA-457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants. Antiviral therapy 2008;13:1083-5
  • Knapp DJHF, Huang S, Harrington R. Stable prevelance of bevirimat-related Gag polymorphisms both before and after HAART exposure. Presented at the 16th conference on retroviruses and opportunistic infections. Montreal, Canada; 8 - 11 February 2009
  • Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71
  • Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999;73:3744-52
  • Malet I, Wirden M, Derache A, et al. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients. AIDS 2007;21:871-3
  • Available from: http://www.hiv.lanl.gov
  • Reicin AS, Ohagen A, Yin L, et al. The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. J Virol 1996;70:8645-52
  • von Schwedler UK, Stemmler TL, Klishko VY, et al. Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly. Embo J 1998;17:1555-68
  • Fitzon T, Leschonsky B, Bieler K, et al. Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication. Virology 2000;268:294-307
  • Tang S, Murakami T, Agresta BE, et al. Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J Virol 2001;75:9357-66
  • Forshey BM, von Schwedler U, Sundquist WI, Aiken C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol 2002;76:5667-77
  • von Schwedler UK, Stray KM, Garrus JE, Sundquist WI. Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol 2003;77:5439-50
  • Ganser-Pornillos BK, von Schwedler UK, Stray KM, et al. Assembly properties of the human immunodeficiency virus type 1 CA protein. J Virol 2004;78:2545-52
  • Gross I, Hohenberg H, Krausslich HG. In vitro assembly properties of purified bacterially expressed capsid proteins of human immunodeficiency virus. Eur J Biochem 1997;249:592-600
  • Gross I, Hohenberg H, Huckhagel C, Krausslich HG. N-Terminal extension of human immunodeficiency virus capsid protein converts the in vitro assembly phenotype from tubular to spherical particles. J Virol 1998;72:4798-810
  • Ganser BK, Li S, Klishko VY, et al. Assembly and analysis of conical models for the HIV-1 core. Science 1999;283:80-3
  • Li S, Hill CP, Sundquist WI, Finch JT. Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 2000;407:409-13
  • Sticht J, Humbert M, Findlow S, et al. A peptide inhibitor of HIV-1 assembly in vitro. Nat Struct Mol Biol 2005;12:671-7
  • Zhang H, Zhao Q, Bhattacharya S, et al. A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J Mol Biol 2008;378:565-80
  • Welker R, Hohenberg H, Tessmer U, et al. Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1. J Virol 2000;74:1168-77
  • Briggs JA, Wilk T, Welker R, et al. Structural organization of authentic, mature HIV-1 virions and cores. Embo J 2003;22:1707-15
  • Benjamin J, Ganser-Pornillos BK, Tivol WF, et al. Three-dimensional structure of HIV-1 virus-like particles by electron cryotomography. J Mol Biol 2005;346:577-88
  • Briggs JA, Grunewald K, Glass B, et al. The mechanism of HIV-1 core assembly: insights from three-dimensional reconstructions of authentic virions. Structure 2006;14:15-20
  • Swanstrom R, Willis JW. Synthesis, assembly and processing of viral proteins. In: Coffin JM, Hughes SH, Varmus HE, editors, Retroviruses. Cold Spring Harbor Laboratory Press,1997. pp 263-334
  • Butan C, Winkler DC, Heymann JB, et al. RSV capsid polymorphism correlates with polymerization efficiency and envelope glycoprotein content: implications that nucleation controls morphogenesis. J Mol Biol 2008;376:1168-81
  • Ganser-Pornillos BK, Cheng A, Yeager M. Structure of full-length HIV-1 CA: a model for the mature capsid lattice. Cell 2007;131:70-9
  • Gamble TR, Vajdos FF, Yoo S, et al. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 1996;87:1285-94
  • Gitti RK, Lee BM, Walker J, et al. Structure of the amino-terminal core domain of the HIV-1 capsid protein. Science 1996;273:231-5
  • Momany C, Kovari LC, Prongay AJ, et al. Crystal structure of dimeric HIV-1 capsid protein. Nat Struct Biol 1996;3:763-70
  • Berthet-Colominas C, Monaco S, Novelli A, et al. Head-to-tail dimers and interdomain flexibility revealed by the crystal structure of HIV-1 capsid protein (p24) complexed with a monoclonal antibody Fab. Embo J 1999;18:1124-36
  • Dorfman T, Bukovsky A, Ohagen A, et al. Functional domains of the capsid protein of human immunodeficiency virus type 1. J Virol 1994;68:8180-7
  • Scholz I, Arvidson B, Huseby D, Barklis E. Virus particle core defects caused by mutations in the human immunodeficiency virus capsid N-terminal domain. J Virol 2005;79:1470-9
  • Lanman J, Lam TT, Barnes S, et al. Identification of novel interactions in HIV-1 capsid protein assembly by high-resolution mass spectrometry. J Mol Biol 2003;325:759-72
  • Lanman J, Lam TT, Emmett MR, et al. Key interactions in HIV-1 maturation identified by hydrogen-deuterium exchange. Nat Struct Mol Biol 2004;11:676-7
  • Mortuza GB, Haire LF, Stevens A, et al. High-resolution structure of a retroviral capsid hexameric amino-terminal domain. Nature 2004;431:481-5
  • Rose S, Hensley DJ, O'Shannessy J, et al. Characterisation of HIV-1 p24 self-association using affinity chromatography. Proteins 1992;13:112-19
  • Datta SA, Curtis JE, Ratcliff W, et al. Conformation of the HIV-1 Gag protein in solution. J Mol Biol 2007;365:812-24
  • Burniston MT, Cimarelli A, Colgan J, et al. Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein. J Virol 1999;73:8527-40
  • Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004;3:301-17
  • Tang C, Loeliger E, Kinde I, et al. Antiviral inhibition of the HIV-1 capsid protein. J Mol Biol 2003;327:1013-20
  • Kelly BN, Kyere S, Kinde I, et al. Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J Mol Biol 2007;373:355-66
  • Barklis E, Alfadhli A, Mcquaw C, et al. Characterization of the in vitro HIV-1 capsid assembly pathway. J Mol Biol 2009;387:376-89
  • Ternois F, Sticht J, Duquerroy S, et al. The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor. Nat Struct Mol Biol 2005;12:678-82
  • Bartonova V, Igonet S, Sticht J, et al. Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein. J Biol Chem 2008;283:32024-33
  • Bhattacharya S, Zhang H, Debnath AK, Cowburn D. Solution structure of a hydrocarbon stapled peptide inhibitor in complex with monomeric C-terminal domain of HIV-1 capsid. J Biol Chem 2008;283:16274-8
  • Abdurahman S, Vegvari A, Youssefi M, et al. Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity. Antimicrob Agents Chemother 2008;52:3737-44
  • Thys K, De Vos S, De Baere I, et al. Performance of a Gag-PR genotyping assay on a cohort of samples retrieved from highly-treatment experienced HIV-1 patients. Presented at the 6th European HIV Drug Resistance Workshop. Budapest, Hungary; 26 – 28 March 2008
  • Rice WG, Supko JG, Malspeis L, et al. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 1995;270:1194-7
  • Ott DE, Hewes SM, Alvord WG, et al. Inhibition of friend virus replication by a compound that reacts with the nucleocapsid zinc finger: anti-retroviral effect demonstrated in vivo. Virology 1998;243:283-92
  • Tavassoli A, Lu Q, Gam J, et al. Inhibition of HIV budding by a genetically selected cyclic peptide targeting the Gag-TSG101 interaction. ACS Chem Biol 2008;3:757-64
  • Waheed AA, Freed EO. Peptide inhibitors of HIV-1 egress. ACS Chem Biol 2008;3:745-7
  • Leitner T, Foley B, Hahn B, et al. HIV sequence compendium. LA-UR 06-06-8. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, USA, 2005
  • Freed EOM. HIVs and their replication. In: Knipe DMH, editor, Fields Virology. Lippincott, Williams & Wilkins, 2007. p. 2107-85

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.